There is an oral PCSK9 treatment (enlicitide) was recently released that provides a 30% reduction, and of course you can't get insurance coverage without the test. And there are 2 drugs with 90%+ reduction in Lp(a) in phase3 trials with expected release in 2027-8, in particular Olpasiran.